BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Ligand Views $36.3M CyDex Acquisition as 'Game Changer'
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ligand Views $36.3M CyDex Acquisition as 'Game Changer'
Jan. 28, 2011
By
Tom Wall
No Comments
Although its $36.3-million acquisition of privately held CyDex Pharmaceuticals Inc., of Lenexa, Kan., is the fourth in the last 28 months for Ligand Pharmaceuticals Inc., CEO John Higgins described it as "transformational" and a "game changer."
BioWorld